EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic value of immunohistochemical staining for H3K27me3 and EZH2 in astrocytoma, IDH-mutant

Shumpei Onishi, Fumiyuki Yamasaki, Vishwa Jeet Amatya, Ushio Yonezawa, Akira Taguchi, Iori Ozono, Novita Ikbar Khairunnisa, Yukari Go, Yukio Takeshima, Nobutaka Horie

Journal of Neuro-Oncology · 2025

DOI: 10.1007/s11060-024-04897-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2025. Verfasst von Shumpei Onishi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshi…. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Astrocytoma, Histones, Isocitrate Dehydrogenase. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hiroshima University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

H3 histone 27 lysine (H3K27) trimethylation (H3K27me3), which is catalyzed by enhancer of zeste homolog 2 (EZH2), regulates gene expression through epigenetic mechanisms. H3K27me3 is used as a diagnostic marker for diffuse midline glioma and as a surrogate marker to distinguish posterior fossa ependymoma A and B. However, the clinical significance of the EZH2–H3K27me3 axis in astrocytoma, IDH-mutant has not been reported, prompting this investigation.

Methods

Thirty-three patients with astrocytoma, IDH-mutant treated at our institute were included in this study. Immunohistochemistry (IHC) targeting H3K27me3, H3K27M, EZH2, EZH inhibitory protein, IDH1-R132H, p53, ATRX, Ki-67, and MTAP was performed. Kaplan–Meier analysis and Cox regression analysis were performed to analyze the correlations of overall survival (OS) and progression-free survival (PFS) with various factors, including age, World Health Organization (WHO) grade, the extent of resection, and immunohistochemical results.

Results

The mean patient age was 40.6 ± 11.0 years. IHC for H3K27me3 was positive in 19 patients and negative in 14 patients. The WHO grade and Ki-67 index were significantly higher in the H3K27me3-positive group ( p = 0.004 and p = 0.024, respectively). OS and PFS were significantly shorter in the H3K27me3-positive group ( p = 0.002 and p = 0.026, respectively). Furthermore, the H3K27me3 and EZH2 double-positive group was associated with a higher WHO grade and higher Ki-67 index ( p = 0.001 and p = 0.024, respectively). In the analysis of patients with WHO grade 2/3, double positivity for H3K27me3 and EZH2 was linked to significantly shorter OS and PFS ( p = 0.0053 and p = 0.0048, respectively).

Conclusion

Positivity for H3K27me3, especially double positivity for H3K27me3 and EZH2, could be a poor prognostic factor for astrocytoma, IDH-mutant. These results suggest the utility of H3K27me3 and EZH2 as candidate markers for estimating the malignancy of astrocytoma, IDH-mutant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinAstrocytomaHistonesIsocitrate DehydrogenaseBrain NeoplasmsMutationBiomarkers, TumorHumansFemaleMaleAdultPrognosisMiddle AgedImmunohistochemistryYoung AdultAdolescentFollow-Up Studies

Stichwörter der Autor:innen

AstrocytomaEZH2GliomaH3K27me3IDH-mutant

Substanzen

Enhancer of Zeste Homolog 2 ProteinHistonesEZH2 protein, humanIsocitrate DehydrogenaseBiomarkers, TumorIDH1 protein, human

Autor:innen und Institutionen

  • Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima, 734-8551, Japan.
  • Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima, 734-8551, Japan. fyama@hiroshima-u.ac.jp.
  • Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Medical Division Technical Center, Hiroshima University, Hiroshima, Japan.

Förderung

  • Hiroshima University

Zitieren

APA

Onishi, S., Yamasaki, F., Amatya, V. J., Yonezawa, U., Taguchi, A., Ozono, I., Khairunnisa, N. I., Go, Y., Takeshima, Y., & Horie, N. (2025). Prognostic value of immunohistochemical staining for H3K27me3 and EZH2 in astrocytoma, IDH-mutant. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04897-8

Vancouver

Onishi S, Yamasaki F, Amatya VJ, Yonezawa U, Taguchi A, Ozono I, et al. Prognostic value of immunohistochemical staining for H3K27me3 and EZH2 in astrocytoma, IDH-mutant. Journal of Neuro-Oncology. 2025. doi:10.1007/s11060-024-04897-8

BibTeX
@article{Onishi2025,
  author = {Onishi, Shumpei and Yamasaki, Fumiyuki and Amatya, Vishwa Jeet and Yonezawa, Ushio and Taguchi, Akira and Ozono, Iori and Khairunnisa, Novita Ikbar and Go, Yukari and Takeshima, Yukio and Horie, Nobutaka},
  title = {Prognostic value of immunohistochemical staining for H3K27me3 and EZH2 in astrocytoma, IDH-mutant},
  journal = {Journal of Neuro-Oncology},
  year = {2025},
  doi = {10.1007/s11060-024-04897-8}
}
Kostenlos starten →